Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Drospirenone is a synthetic progestin widely utilized in modern hormonal contraception and hormone replacement therapy. Chemically, it belongs to the class of spironolactone derivatives, distinguished by its unique anti-mineralocorticoid activity which mimics the effects of natural progesterone while blocking aldosterone receptors. This specific mechanism differentiates it from many other progestins used in oral contraceptives, offering significant clinical benefits regarding fluid retention and metabolic profile. The molecular formula of Drospirenone is C24H30O3, reflecting its complex steroid structure composed of twenty-four carbon atoms, thirty hydrogen atoms, and three oxygen atoms. Its corresponding Chemical Abstracts Service (CAS) registry number is 67392-87-4, serving as a unique identifier for regulatory and pharmaceutical tracking globally.
In clinical practice, Drospirenone is most commonly prescribed in combination with ethinyl estradiol to form oral contraceptive pills. It effectively prevents ovulation through negative feedback on the hypothalamic-pituitary-gonadal axis, thereby providing highly reliable birth control. Beyond contraception, this compound is valued for its ability to counteract estrogen-induced water retention due to its antimineralocorticoid properties. Patients often experience reduced bloating, weight fluctuations, and premenstrual symptoms when using formulations containing Drospirenone compared to those with older progestins. Additionally, it is indicated for the treatment of moderate acne vulgaris and premenstrual dysphoric disorder (PMDD), leveraging its anti-androgenic effects to improve skin conditions and mood stability.
The drug is generally well-tolerated, though like all hormonal agents, it carries potential risks such as thromboembolic events, particularly in smokers or individuals with specific cardiovascular risk factors. Regular medical supervision is essential to monitor blood pressure and electrolyte levels, as the mineralocorticoid blockade can occasionally lead to hyperkalemia, especially in patients with renal impairment or those taking potassium-sparing diuretics. Despite these considerations, Drospirenone remains a cornerstone in gynecological pharmacology, offering a multifaceted therapeutic approach that addresses fertility control, dermatological health, and menstrual symptom management simultaneously. Its widespread availability and established safety profile continue to make it a preferred choice for millions of women worldwide seeking effective hormonal regulation.